Semaglutide vs Tirzepatide vs Retatrutide: Receptor Profiles and Analytical Differences

Semaglutide is a modified human GLP-1(7-37) with an alpha-aminoisobutyric acid at position 8 to blunt DPP-4 cleavage, an arginine at position 34, and a C18 fatty diacid attached through a linker to the lysine at position 26. Its formula is C187H291N45O59 and its average molecular weight 4113.58 Da.

Tirzepatide is a 39-residue peptide built on a GIP scaffold rather than a GLP-1 one, engineered so that a single sequence binds both the GIP receptor and the GLP-1 receptor. A C20 fatty diacid is conjugated through the lysine at position 20. Its formula is C225H348N48O68 and its average molecular weight 4813.45 Da.

Retatrutide extends the same idea to a third receptor by adding glucagon receptor activity to the GIP and GLP-1 engagement. Its formula is C221H342N46O68 and its molecular weight 4731.4 Da. Two related compounds complete the class in the Certus catalog: survodutide, a GLP-1/glucagon dual agonist, and cagrilintide, a long-acting amylin receptor analog that is often paired with a GLP-1 agonist in published work because the two act through separate receptor systems.

All three receptors are class B G protein-coupled receptors signaling principally through Gs and cAMP, so the standard in vitro readout for any of these compounds is cAMP accumulation in a cell line expressing the receptor of interest. What differs is which receptors respond.

Semaglutide is a potent, selective GLP-1 receptor agonist with negligible activity at GIPR or the glucagon receptor. That selectivity is what makes it the reference compound for GLP-1R work. Tirzepatide's pharmacology is asymmetric: in published receptor assays it is a full agonist at GIPR and a biased partial agonist at GLP-1R, with weaker beta-arrestin recruitment at GLP-1R than native GLP-1. Which receptor contributes what is itself an active research question, and a study that needs to separate the two arms typically runs semaglutide alongside a selective GIPR ligand as controls.

Retatrutide adds glucagon receptor agonism, so it is the compound for work that asks what glucagon receptor signaling contributes on top of dual incretin engagement, and it needs three receptor assays rather than two to characterize. Survodutide covers the GLP-1 and glucagon pair without GIPR, which makes it the natural comparator for isolating the GIP arm.

The fatty diacid is what separates these compounds from the native hormones analytically. A C18 or C20 diacid, attached through a glutamate and oligo-ethylene glycol linker to a lysine side chain, gives the molecule a hydrophobic tail that binds reversibly to serum albumin. Together with the position 8 substitution that resists DPP-4, this is what extends the circulating half-life from minutes to days in published pharmacokinetic work.

For the analyst, the acyl chain does three things. It makes the peptide much more hydrophobic than its sequence would predict, so it elutes late on reversed phase. It adds a large, well-defined mass that must be confirmed. And it creates a characteristic impurity: the des-acyl peptide, where the fatty acid was never attached or was lost, which is a different molecule with different receptor behavior and none of the albumin binding.

Semaglutide's acyl moiety contributes roughly 700 Da to the total mass, and tirzepatide's slightly more. A lot that is largely des-acyl still gives a clean HPLC main peak; only the mass spectrometer catches it.

A 4,100 to 4,800 Da peptide under electrospray ionization carries multiple charges, producing an envelope of m/z peaks at +3, +4, +5 and so on. Deconvoluting that envelope gives the intact mass, which the certificate compares against theory with a tolerance of 1.0 Da. At that tolerance a single-residue deletion (57 Da for glycine, more for anything else) is unmistakable, a missing acyl chain is unmistakable, and an incompletely removed protecting group (a tert-butyl at 56 Da, a Pbf on arginine at 252 Da) is unmistakable.

These are exactly the failure modes of this class. The syntheses are long, 31 to 39 residues with an acylation step and several orthogonally protected side chains, and deletion sequences and incomplete deprotection are the usual defects. Retatrutide is the least mature chemistry of the three and the least forgiving; Certus holds retatrutide lots in quarantine for a second independent assay run before release rather than shipping on one certificate.

HPLC alone is not enough for this class because the sequences are close enough to each other, and to other incretin analogs, that a single peak at the expected retention time is consistent with several molecules. Every Certus lot in the metabolic category is released on reversed-phase area percent and electrospray LC-MS with the deconvoluted spectrum published on the certificate.

Tirzepatide is the longest and most hydrophobic of the three, elutes latest, and is the most prone to aggregation when reconstituted carelessly. Certus releases tirzepatide lots only after a post-reconstitution clarity check in addition to the standard panel. Semaglutide is somewhat better behaved but shares the same sensitivity to shear: vigorous mixing generates an air-water interface, the peptide denatures there, and the visible sign is foam.

Cagrilintide, engineered to stay in solution where native amylin forms fibrils, is still the compound in the class most sensitive to pH; acidic diluents measurably shorten its solution stability, and lots are released with a supplementary dynamic light scattering check for aggregates. Survodutide is supplied as a trifluoroacetate salt and residual TFA is reported on the certificate because it matters for sensitive cell lines.

All five are stored lyophilized at -20 °C protected from light, and retatrutide additionally desiccated. Reconstituted stock is held at 2-8 °C. Semaglutide dissolves faster in slightly alkaline buffer, tirzepatide recovers better if the vial is warmed to room temperature before diluent is added, and none of them should be shaken.

The dominant cause of measurable potency loss in this class is repeated freeze-thaw of reconstituted stock, not synthesis quality. Reconstitute and aliquot in a single session, freeze once, and thaw each aliquot once. The general reasoning is in the reconstitution guide; the specific note on every product page in this category says the same thing because it is the same failure.

The lines that carry the weight are the LC-MS observed mass against theory, the deconvoluted spectrum itself rather than a summary, the HPLC chromatogram showing the main peak and the late-eluting region where des-acyl and deletion species appear, net peptide content, and water content. The release specification is 99.0 % for semaglutide and tirzepatide and 98.0 % for retatrutide, cagrilintide and survodutide, reflecting how hard each synthesis is.

If a certificate for any of these compounds shows only an HPLC purity, it has not established identity. The mass is the line that distinguishes tirzepatide from a des-acyl tirzepatide, or retatrutide from a deletion sequence, and it is the line a buyer of this class should read first.